Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Deciphera Pharmaceuticals Inc (DCPH)

Deciphera Pharmaceuticals Inc (DCPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 878,038
  • Shares Outstanding, K 66,217
  • Annual Sales, $ 96,150 K
  • Annual Income, $ -299,960 K
  • 60-Month Beta 1.19
  • Price/Sales 9.06
  • Price/Cash Flow N/A
  • Price/Book 3.21
Trade DCPH with:

Options Overview Details

View History
  • Implied Volatility 78.79% ( -3.91%)
  • Historical Volatility 72.91%
  • IV Percentile 20%
  • IV Rank 11.33%
  • IV High 208.73% on 11/05/21
  • IV Low 62.19% on 08/05/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 213
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 5,497
  • Open Int (30-Day) 4,830

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.66
  • Number of Estimates 7
  • High Estimate -0.55
  • Low Estimate -0.73
  • Prior Year -1.21
  • Growth Rate Est. (year over year) +45.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.14 +30.77%
on 06/13/22
14.48 -8.43%
on 06/24/22
+2.41 (+22.21%)
since 06/01/22
3-Month
9.01 +47.17%
on 05/09/22
14.48 -8.43%
on 06/24/22
+3.35 (+33.80%)
since 04/01/22
52-Week
6.51 +103.69%
on 03/08/22
14.48 -8.43%
on 06/24/22
+3.97 (+42.77%)
since 07/01/21

Most Recent Stories

More News
Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry

Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved to treat rare cancer and other rare diseases, has seen strong uptake since approval. However, stiff competition remains a concern.

RHHBY : 42.0100 (+0.72%)
BPMC : 49.93 (-1.15%)
DCPH : 13.26 (+0.84%)
LPTX : 1.1700 (+1.74%)
Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Chief Business Officer

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced the appointment of Kelley Dealhoy as Senior Vice President and Chief Business Officer. Ms. Dealhoy brings 20 years of life science leadership...

DCPH : 13.26 (+0.84%)
Deciphera (DCPH) Up More Than 30% in Past 3 Months: Here's Why

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.

AGLE : 0.5101 (+0.99%)
DCPH : 13.26 (+0.84%)
LPTX : 1.1700 (+1.74%)
DTIL : 1.5300 (-4.38%)
Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that members of the management team will participate in fireside chats at the following investor conferences:

DCPH : 13.26 (+0.84%)
Deciphera (DCPH) Down Despite Narrower-Than-Expected Q1 Loss

Deciphera (DCPH) reports narrower-than-expected loss in the first quarter of 2022 while revenues beat estimates.

NVS : 84.36 (-0.20%)
VRTX : 287.32 (+1.96%)
DCPH : 13.26 (+0.84%)
APLT : 0.8650 (-8.77%)
Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Fall Y/Y

Puma Biotech (PBYI) Q1 loss narrows while sales come in line with estimates. PBYI's stock declines in the after-market trading session following the news.

RHHBY : 42.0100 (+0.72%)
ALKS : 30.53 (+2.48%)
PBYI : 2.78 (-2.46%)
DCPH : 13.26 (+0.84%)
Vertex (VRTX) Q1 Earnings Lag, Sales Top, Expense View Tweaked

Vertex Pharmaceuticals' (VRTX) earnings miss estimates while sales beat the same for the first quarter of 2022. The company maintains its revenue guidance for 2022.

ALKS : 30.53 (+2.48%)
VRTX : 287.32 (+1.96%)
CRSP : 63.79 (+4.97%)
DCPH : 13.26 (+0.84%)
Amarin (AMRN) Q1 Earnings & Sales Hurt by Vascepa Generics

Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and COVID-related disruptions during the first quarter. The company's stock falls significantly on May 4.

ALKS : 30.53 (+2.48%)
AMRN : 1.4400 (-3.36%)
BGNE : 166.95 (+3.15%)
DCPH : 13.26 (+0.84%)
Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss

Clovis (CLVS) incurs wider-than-estimated loss for first-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.

BMY : 76.84 (-0.21%)
VRTX : 287.32 (+1.96%)
CLVS : 2.85 (+58.33%)
DCPH : 13.26 (+0.84%)
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Tops Revenue Estimates

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 4.76% and 7.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the...

DCPH : 13.26 (+0.84%)
NGM : 12.78 (-0.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Deciphera Pharmaceuticals, Inc. develops small molecule kinase inhibitors for cancer, utilizing its proprietary kinase switch control inhibitor platform.

See More

Key Turning Points

3rd Resistance Point 14.90
2nd Resistance Point 14.16
1st Resistance Point 13.71
Last Price 13.26
1st Support Level 12.52
2nd Support Level 11.77
3rd Support Level 11.32

See More

52-Week High 14.48
Last Price 13.26
Fibonacci 61.8% 11.44
Fibonacci 50% 10.49
Fibonacci 38.2% 9.55
52-Week Low 6.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar